Zobrazeno 1 - 10
of 113
pro vyhledávání: '"Bernt Johan von Scholten"'
Autor:
Asger Wretlind, Viktor Rotbain Curovic, Andressa de Zawadzki, Tommi Suvitaival, Jin Xu, Emilie Hein Zobel, Bernt Johan von Scholten, Rasmus Sejersten Ripa, Andreas Kjaer, Tine Willum Hansen, Tina Vilsbøll, Henrik Vestergaard, Peter Rossing, Cristina Legido-Quigley
Publikováno v:
Lipids in Health and Disease, Vol 22, Iss 1, Pp 1-12 (2023)
Abstract Background Specific ceramides have been identified as risk markers for cardiovascular disease (CVD) years before onset of disease. Treatment with the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide has been shown to induce ben
Externí odkaz:
https://doaj.org/article/81dad782fa1040f5abe1e046c103c5d3
Autor:
Tanja Fredensborg Holm, Flemming Witt Udsen, Kristine Færch, Morten Hasselstrøm Jensen, Bernt Johan von Scholten, Ole Kristian Hejlesen, Stine Hangaard
Publikováno v:
JMIR Research Protocols, Vol 13, p e50340 (2024)
BackgroundThere has been an increasing interest in the use of digital health lifestyle interventions for people with prediabetes, as these interventions may offer a scalable approach to preventing type 2 diabetes. Previous systematic reviews on digit
Externí odkaz:
https://doaj.org/article/830d824e99ce41c9a0ecde410fc7cdf8
Autor:
Christina Gjerlev Poulsen, Daniel G K Rasmussen, Federica Genovese, Tine W Hansen, Signe Holm Nielsen, Henrik Reinhard, Bernt Johan von Scholten, Peter K Jacobsen, Hans-Henrik Parving, Morten Asser Karsdal, Peter Rossing, Marie Frimodt-Møller
Publikováno v:
PLoS ONE, Vol 18, Iss 3, p e0283296 (2023)
BackgroundDiabetic kidney disease is a major cause of morbidity and mortality. Dysregulated turnover of collagen type III is associated with development of kidney fibrosis. We investigated whether a degradation product of collagen type III (C3M) was
Externí odkaz:
https://doaj.org/article/a8daa49ec3fa47a8b2d9480bc92d61d8
Autor:
Frederik F. Kreiner, Philip Andreas Schytz, Hiddo J. L. Heerspink, Bernt Johan von Scholten, Thomas Idorn
Publikováno v:
Biomedicines, Vol 11, Iss 9, p 2498 (2023)
Obesity is a serious chronic disease and an independent risk factor for the new onset and progression of chronic kidney disease (CKD). CKD prevalence is expected to increase, at least partly due to the continuous rise in the prevalence of obesity. Th
Externí odkaz:
https://doaj.org/article/b992077fcd914823b4e3a831ed8cf741
Publikováno v:
Frontiers in Physiology, Vol 13 (2022)
Heart failure (HF) remains one of the cardiovascular diseases (CVDs) associated with a high unmet medical need due to high morbidity and mortality rates and lack of efficacious interventions. HF is closely related to cardiometabolic diseases such as
Externí odkaz:
https://doaj.org/article/e6c69c2ef92949dbb91d6ebbd3fb8525
Autor:
Bernt Johan von Scholten, Frederik Flindt Kreiner, Søren Rasmussen, Peter Rossing, Thomas Idorn
Publikováno v:
Therapeutic Advances in Endocrinology and Metabolism, Vol 13 (2022)
Chronic kidney disease (CKD) affects around 10% of the global population and is most often caused by diabetes. Diabetes with CKD (diabetic kidney disease, DKD) is a progressive condition that may cause kidney failure and which contributes significant
Externí odkaz:
https://doaj.org/article/a6819ebf4df049a981b166c896ee48dc
Autor:
Suvanjaa Sivalingam, Emil List Larsen, Daniel H. van Raalte, Marcel H. A. Muskiet, Mark M. Smits, Lennart Tonneijck, Jaap A. Joles, Bernt Johan von Scholten, Emilie Hein Zobel, Frederik Persson, Trine Henriksen, Lars Jorge Diaz, Tine W. Hansen, Henrik Enghusen Poulsen, Peter Rossing
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract Glucagon-like peptide 1 receptor agonists have shown cardioprotective effects which have been suggested to be mediated through inhibition of oxidative stress. We investigated the effect of treatment with a glucagon-like peptide 1 receptor ag
Externí odkaz:
https://doaj.org/article/3bcc699d77684b339336dcb21eb97295
Autor:
Asger Wretlind, Emilie Hein Zobel, Andressa de Zawadzki, Rasmus Sejersten Ripa, Viktor Rotbain Curovic, Bernt Johan von Scholten, Ismo Matias Mattila, Tine Willum Hansen, Andreas Kjær, Henrik Vestergaard, Peter Rossing, Cristina Legido-Quigley
Publikováno v:
Frontiers in Clinical Diabetes and Healthcare, Vol 3 (2022)
BackgroundLiraglutide is a glucose-lowering medication used to treat type 2 diabetes and obesity. It is a GLP-1 receptor agonist with downstream metabolic changes beyond the incretin system, such as reducing the risk of cardiovascular complications.
Externí odkaz:
https://doaj.org/article/9a83d2ed45e7427bba080f2aa328deb5
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
Externí odkaz:
https://doaj.org/article/d2e501593ee645158e82b52431372017
Autor:
Jens Christian Laursen, Ida Kirstine B. Rasmussen, Emilie H. Zobel, Philip Hasbak, Bernt Johan von Scholten, Lene Holmvang, Rasmus S. Ripa, Christian S. Hansen, Marie Frimodt-Moeller, Andreas Kjaer, Peter Rossing, Tine W. Hansen
Publikováno v:
Frontiers in Endocrinology, Vol 12 (2021)
BackgroundThe mechanisms linking cardiovascular autonomic neuropathy, diabetic kidney disease and cardiovascular mortality in type 2 diabetes are widely unknown. We investigated the relationship between baseline cardiovascular autonomic function and
Externí odkaz:
https://doaj.org/article/ce4f960c1e1348f4ab441a68540b69dc